DK3455625T3 - Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi - Google Patents

Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi Download PDF

Info

Publication number
DK3455625T3
DK3455625T3 DK17726208.6T DK17726208T DK3455625T3 DK 3455625 T3 DK3455625 T3 DK 3455625T3 DK 17726208 T DK17726208 T DK 17726208T DK 3455625 T3 DK3455625 T3 DK 3455625T3
Authority
DK
Denmark
Prior art keywords
immunteraphy
antenges
neo
predicting
applicability
Prior art date
Application number
DK17726208.6T
Other languages
English (en)
Inventor
Ugur Sahin
Barbara Schrörs
Sebastian Boegel
Martin Löwer
Mathias Vormehr
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK3455625T3 publication Critical patent/DK3455625T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK17726208.6T 2016-05-13 2017-05-10 Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi DK3455625T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number Publication Date
DK3455625T3 true DK3455625T3 (da) 2020-10-26

Family

ID=55971007

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20193183.9T DK3792628T3 (da) 2016-05-13 2017-05-10 Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi
DK17726208.6T DK3455625T3 (da) 2016-05-13 2017-05-10 Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20193183.9T DK3792628T3 (da) 2016-05-13 2017-05-10 Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi

Country Status (27)

Country Link
US (2) US12153041B2 (da)
EP (3) EP3792628B1 (da)
JP (5) JP7529381B2 (da)
KR (3) KR20220020993A (da)
CN (1) CN109073637A (da)
AU (2) AU2017264546B2 (da)
BR (1) BR112018073221A2 (da)
CA (1) CA3022654A1 (da)
CY (1) CY1123520T1 (da)
DK (2) DK3792628T3 (da)
ES (2) ES2980781T3 (da)
FI (1) FI3792628T3 (da)
HR (2) HRP20201671T1 (da)
HU (2) HUE052240T2 (da)
IL (2) IL300841B1 (da)
LT (2) LT3792628T (da)
MA (1) MA43794B1 (da)
MD (1) MD3455625T2 (da)
MX (2) MX393653B (da)
PL (2) PL3792628T3 (da)
PT (2) PT3455625T (da)
RS (2) RS61071B1 (da)
SG (1) SG11201808495SA (da)
SI (2) SI3455625T1 (da)
SM (2) SMT202000622T1 (da)
WO (2) WO2017194170A1 (da)
ZA (1) ZA201805809B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102833333B1 (ko) 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3631471A4 (en) 2017-05-30 2021-06-30 Nant Holdings IP, LLC Circulating tumor cell enrichment using neoepitopes
KR102267463B1 (ko) * 2018-02-15 2021-06-21 코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠 암 항원 펩티드
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CA3132041A1 (en) * 2019-03-06 2020-09-10 Gritstone Bio, Inc. Identification of neoantigens with mhc class ii model
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
EP4392140A1 (en) 2021-08-24 2024-07-03 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1276896B1 (en) * 2000-04-28 2010-07-21 Mannkind Corporation Epitope synchronization in antigen presenting cells
CA2415902A1 (en) 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
ATE389668T1 (de) * 2000-07-31 2008-04-15 Greenpeptide Co Ltd Tumorantigen
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
CA2603191A1 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US20120039806A1 (en) 2009-03-23 2012-02-16 Mireille Hanna Lahoud Compounds and Methods for Modulating an Immune Response
WO2011050344A2 (en) * 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012164004A1 (en) * 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3612965A4 (en) 2017-04-19 2021-01-13 Gritstone Oncology, Inc. NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE
KR102729393B1 (ko) 2017-06-09 2024-11-13 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2019050994A1 (en) 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
IL276839B1 (en) 2018-02-27 2026-05-01 Gritstone Bio Inc Neoantigen identification using pan-allelic models

Also Published As

Publication number Publication date
DK3792628T3 (da) 2024-06-17
RU2018137721A (ru) 2020-06-15
CA3022654A1 (en) 2017-11-16
HRP20240704T1 (hr) 2024-09-27
AU2022209286A1 (en) 2022-08-25
EP3455625B1 (en) 2020-09-02
JP2024112805A (ja) 2024-08-21
EP3792628B1 (en) 2024-04-24
EP4411376A2 (en) 2024-08-07
KR102358620B1 (ko) 2022-02-07
EP4411376A3 (en) 2025-03-19
US20250244311A1 (en) 2025-07-31
SMT202000622T1 (it) 2021-01-05
HRP20201671T1 (hr) 2021-03-05
EP3455625A1 (en) 2019-03-20
KR20240146087A (ko) 2024-10-07
IL262680B1 (en) 2023-04-01
HUE052240T2 (hu) 2021-04-28
RS61071B1 (sr) 2020-12-31
BR112018073221A2 (pt) 2019-02-19
US12153041B2 (en) 2024-11-26
WO2017194170A1 (en) 2017-11-16
KR20220020993A (ko) 2022-02-21
JP2024160216A (ja) 2024-11-13
PL3455625T3 (pl) 2021-01-25
IL262680A (en) 2018-12-31
CN109073637A (zh) 2018-12-21
SI3792628T1 (sl) 2024-08-30
ZA201805809B (en) 2020-12-23
MD3455625T2 (ro) 2020-12-31
ES2826480T3 (es) 2021-05-18
MA43794B1 (fr) 2020-12-31
ES2980781T3 (es) 2024-10-03
IL300841B1 (en) 2026-05-01
JP2024096712A (ja) 2024-07-17
EP3792628A2 (en) 2021-03-17
IL300841A (en) 2023-04-01
AU2017264546A1 (en) 2018-10-18
WO2017194610A1 (en) 2017-11-16
EP3792628A3 (en) 2021-05-19
LT3792628T (lt) 2024-06-25
IL262680B2 (en) 2023-08-01
SMT202400232T1 (it) 2024-07-09
JP2019520554A (ja) 2019-07-18
CY1123520T1 (el) 2022-03-24
MX2022007902A (es) 2022-07-21
LT3455625T (lt) 2021-01-11
PT3455625T (pt) 2020-10-22
KR20190008218A (ko) 2019-01-23
MX393653B (es) 2025-03-24
MA43794A (fr) 2019-03-20
JP7529381B2 (ja) 2024-08-06
HUE067497T2 (hu) 2024-10-28
RS65568B1 (sr) 2024-06-28
PT3792628T (pt) 2024-06-18
JP2022081492A (ja) 2022-05-31
FI3792628T3 (fi) 2024-06-07
PL3792628T3 (pl) 2024-07-15
MX2018013081A (es) 2019-01-24
SG11201808495SA (en) 2018-10-30
RU2018137721A3 (da) 2020-08-25
AU2017264546B2 (en) 2022-04-28
SI3455625T1 (sl) 2021-01-29
US20190178871A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3512959T3 (da) Fremgangsmåder til udførelse af multipleks PCR
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK4008782T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
FIC20250033I1 (fi) nemolitsumabi
DK3473783T3 (da) Fremgangsmåde til fremstilling af gulvplader
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3317394T3 (da) Anordning til opformering af mikrovæv
DK3198035T3 (da) Fremgangsmåder til forudsigelse af medicinrespons
DK3940352T3 (da) Fremgangsmåde til diagnosticering af vægte
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3126373T3 (da) Fremgangsmåde til fremstilling af amg 416
DK3507408T3 (da) Fremgangsmåde til fremstilling af nonwoven
DK3344805T3 (da) Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider